R-Gemcitabine (1000mg/m2) Oxaliplatin Therapy - 14 day. NCCP National SACT Regimen. HSE.
Regulatory approval published by the Health Service Executive.
Citation
Regulatory approvals
Approved indications from this document for cancer drugs containing at least one biomarker.
| Indication | Statements |
|---|---|
| Relapsed or refractory CD20 positive diffuse large B cell lymphoma in patients ineligible for stem cell transplant. | 2 |
Therapeutic response
Precision oncology relationships for therapeutic response derived from this document.
| Type | Biomarker(s) | Cancer type | Therapy(ies) | |
|---|---|---|---|---|
| Sensitivity (+) | CD20 + | Diffuse Large B-Cell Lymphoma | Gemcitabine, Oxaliplatin, Rituximab | |
| Sensitivity (+) | CD20 + | Non-Hodgkin Lymphoma | Gemcitabine, Oxaliplatin, Rituximab |